ArticleESMO real world data and digital oncology2025
Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancer.
Article in ESMO real world data and digital oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Neoadjuvant therapy for stage II-III triple-negative breast cancer: Current evidence, clinical boundaries and emerging strategies (Review).Oncology letters · 2026Review
- Developing and evaluating definitions of real-world clinical endpoints for patients with early-stage triple-negative breast cancer using a United States of America secondary database.ESMO real world data and digital oncology · 2026Article
- Real-world outcome of neoadjuvant therapy with or without pembrolizumab for triple-negative breast cancer.Acta oncologica (Stockholm, Sweden) · 2026Article
- Biomarker-driven neoadjuvant immunotherapy in triple-negative breast cancer: emerging therapeutic targets FOXP3 and WT1.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pembrolizumab-based neoadjuvant chemoimmunotherapy (CIT) is the new standard of care for high-risk early triple-negative breast cancer (eTNBC). The addition of multiple cytotoxic drugs can lead to cumulative toxicities. We report the evolution of chemotherapy (CT) practice and its impact on completion and effectiveness of subsequent regimens in a real-world setting. Patients and methods: We conducted an ambispective, observational study of patients with eTNBC at a comprehensive cancer centre between February 2019 and February 2024. All data were extracted from electronic health records and manually curated. Results: Of the 366 patients enrolled, 247 received neoadjuvant CT and 119 received CIT. Grade 3/4 toxicities were more common in the CIT group (78.2% versus 58.6%, Conclusions: Escalation of neoadjuvant CIT in TNBC increases toxicity and leads to significant dose reductions without affecting the improvement in pCR rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.